These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22778010)

  • 1. General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Butt Z; Peipert J; Webster K; Chen C; Cella D
    Cancer; 2013 Jan; 119(2):429-37. PubMed ID: 22778010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Rao D; Butt Z; Rosenbloom S; Robinson D; Von Roenn J; Kuzel TM; Cella D
    J Pain Symptom Manage; 2009 Aug; 38(2):291-8. PubMed ID: 19356897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
    Trask PC; Bushmakin AG; Cappelleri JC; Tarazi J; Rosbrook B; Bycott P; Kim S; Stadler WM; Rini B
    J Cancer Surviv; 2011 Sep; 5(3):255-62. PubMed ID: 21476015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Cella D; Yount S; Du H; Dhanda R; Gondek K; Langefeld K; George J; Bro WP; Kelly C; Bukowski R
    J Support Oncol; 2006 Apr; 4(4):191-9. PubMed ID: 16669463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
    Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
    Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
    Luo X; Cappelleri JC; Cella D; Li JZ; Charbonneau C; Kim ST; Chen I; Motzer RJ
    Value Health; 2009 Jun; 12(4):580-6. PubMed ID: 19900256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure.
    Rosenblad AK; Sundqvist P; Westman B; Ljungberg B
    Qual Life Res; 2021 Sep; 30(9):2663-2670. PubMed ID: 33846957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
    Cella D; Motzer RJ; Rini BI; Cappelleri JC; Ramaswamy K; Hariharan S; Arondekar B; Bushmakin AG
    Value Health; 2018 Dec; 21(12):1413-1418. PubMed ID: 30502785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
    Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
    Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
    Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
    J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
    Cella D; Michaelson MD; Bushmakin AG; Cappelleri JC; Charbonneau C; Kim ST; Li JZ; Motzer RJ
    Br J Cancer; 2010 Feb; 102(4):658-64. PubMed ID: 20104222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
    Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
    Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Four-Dimensional Symptom Questionnaire (4DSQ) in the general population: scale structure, reliability, measurement invariance and normative data: a cross-sectional survey.
    Terluin B; Smits N; Brouwers EP; de Vet HC
    Health Qual Life Outcomes; 2016 Sep; 14(1):130. PubMed ID: 27629535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement invariance and general population reference values of the PROMIS Profile 29 in the UK, France, and Germany.
    Fischer F; Gibbons C; Coste J; Valderas JM; Rose M; Leplège A
    Qual Life Res; 2018 Apr; 27(4):999-1014. PubMed ID: 29350345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
    Lai JS; Beaumont JL; Diaz J; Khan S; Cella D
    Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
    Litwin MS; Fine JT; Dorey F; Figlin RA; Belldegrun AS
    J Urol; 1997 May; 157(5):1608-12. PubMed ID: 9112487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.
    Rothrock NE; Jensen SE; Beaumont JL; Abernethy AP; Jacobsen PB; Syrjala K; Cella D
    Value Health; 2013; 16(5):789-96. PubMed ID: 23947972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.